Danaher Corp /De/ (DHR) Stock Price & Analysis
Danaher Corp /De/ (DHR) fell 0.52% to USD 191.5 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
DHR last closed at USD 192.5; the session ranged USD 190–194.8 on volume of 5,964,050 shares. Market capitalization is $134.62B, with a 52-week range of USD 160.93–242.8 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 191.5 |
|---|---|
| Change | ▼ 0.52% (down) |
| Previous Close | USD 192.5 |
| Open | USD 193.08 |
| Day Range | USD 190 – 194.8 |
| 52-Week Range | USD 160.93 – 242.8 |
| Volume | 5,964,050 shares |
| Market Cap | $134.62B |
| Exchange | NYQ |
Technical Analysis (DHR)
Nexqual's technical model rates DHR "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.55 (neutral) |
| vs SMA50 | Above (USD 184.48) |
| MACD | 1.36 (positive) |
Analyst Ratings (DHR)
Wall Street analysts rate DHR "Strong Buy" based on 23 analysts, with a mean price target of USD 227.61 (range USD 195–310), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 227.61 |
| High Target | USD 310 |
| Low Target | USD 195 |
| Buy / Hold / Sell | 22 / 4 / 0 |
Earnings (DHR)
| Next Earnings Date | 2026-10-20 |
|---|---|
| EPS Estimate | USD 1.91 |
| Revenue Estimate | $6.54B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.94 vs est 1.85 ▲ beat |
| 2026-03-31 | USD 2.06 vs est 1.94 ▲ beat |
| 2025-12-31 | USD 2.23 vs est 2.19 ▲ beat |
| 2025-09-30 | USD 1.89 vs est 1.72 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (DHR)
| Total Revenue | $25.11B |
|---|---|
| Revenue Growth (YoY) | +5.50% |
| Gross Margin | +58.75% |
| Operating Margin | +19.78% |
| Profit Margin | +15.95% |
| ROE | +7.61% |
| Debt / Equity | 52.97 |
| Current Ratio | 1.65 |
| Total Cash | $4.35B |
| Total Debt | $27.86B |
| Free Cash Flow | $4.33B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (DHR)
Nexqual rates Danaher Corp /De/'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Mixed — Revenue +2.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 20% |
| Balance Sheet | Solid — $4.35B cash vs $27.9B debt |
| Cash Flow | Strong — FCF $4.33B, 18% margin |
| Efficiency | Mixed — ROE 8%, ROA 3.9% |
Ownership (DHR)
| Insider Ownership | +10.81% |
|---|---|
| Institutional Ownership | +84.85% |
| Shares Outstanding | 702.99M |
| Float | 625.84M |
| Short % of Float | +1.72% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (DHR)
Danaher Corp /De/ is led by Rainer M. Blair (age 61), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:13 UTC.
| President, CEO & Director | Rainer M. Blair (age 61) |
|---|---|
| Co-Founder & Chairman | Steven M. Rales (age 74) |
| Co-Founder & Director | Mitchell P. Rales (age 68) |
| Executive Vice President | Matthew R. McGrew (age 53) |
| Executive Vice President of Diagnostics Platform | Julie Sawyer Montgomery (age 52) |
Major Backers & Investors (DHR)
Notable institutional backers of Danaher Corp /De/ include FMR, LLC, JPMorgan, Price (T.Rowe) Associates Inc, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 3.21% |
| JPMorgan | 2.41% |
| Price (T.Rowe) Associates Inc | 2.18% |
| Wellington Management | 2.1% |
| Capital International Investors | 1.99% |
| Fidelity | 1.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.07% |
| BlackRock | 8.53% |
| State Street | 5.05% |
| Geode Capital | 2.01% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Danaher Corp /De/'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
- The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
- The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | USD 568.26 | ▲ 7.94% |
| SYK | Stryker Corporation | USD 330.25 | ▲ 6.79% |
| BDX | Becton, Dickinson and Company | USD 156.36 | ▲ 2.09% |
| ZTS | Zoetis Inc. | USD 75.35 | ▲ 1.56% |
| ECL | Ecolab Inc. | USD 268.75 | ▲ 0.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.